Prothena | PRTA - 债务



金融业
股票价格
USD
资产
USD 302.58M
现金及等价物
USD 288.19M
销售成本
USD 28.94M
流动资产
USD 292.01M
流动负债
USD 11.66M
债务
USD 7.65M
EBIT
USD 25.79M
EBITDA
USD 25.98M
员工
163
EPS每股收益
USD 0.6
股本和储备
USD 286.89M
销售毛利
USD 51.08M
债务利息支出
USD 302.58M
利息收入
USD 2.42M
贷款资金
USD 0
市值
USD 471.7M
净收入
USD 32.72M
营业费用
USD 25.29M
营业利润
USD 25.79M
普通股股本
USD 53.08M
PE价格收益
22.11
税前利润
USD 32.72M
销售收入
USD 51.08M
销售和管理费用
USD 12.67M
贸易债权人
USD 1.94M
应收帐款人
USD 5.16M


债务 更改 日
Acadia Pharmaceuticals USD 50.79M 1.39M 2026-03
Agios Pharmaceuticals USD 35.74M 4.46M 2026-03
Akebia Therapeutics USD 46.51M 7.82M 2025-03
ALKERMES USD 1.58B 1.51B 2026-03
Alnylam Pharmaceuticals USD 1.27B 5.33M 2026-03
Amgen USD 57.32B 2.72B 2026-03
Biogen USD 8.09B 1.53B 2026-06
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Exelixis USD 165.93M 3.61M 2026-06
Immunic USD 0 0 2024-06
Incyte USD 38.27M 1.16M 2026-06
Ionis Pharmaceuticals USD 1.91B 425.5M 2026-06
MacroGenics USD 36.51M 500K 2026-03
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Prothena USD 7.65M 1.43M 2026-03
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vertex Pharmaceuticals USD 1.98B 8.9M 2026-06